Daiichi Sankyo’s cancer drug wins the FDA’s coveted ‘breakthrough’ tag

Damian Garde Daiichi Sankyo picked up the FDA's breakthrough therapy designation for a Phase III cancer drug, putting it in line for preferential access to agency experts as it ...

Grifols bags €100M for Alzheimer’s R&D; Ipsen inks $137M cancer deal; Oryzon raises €17M

Nick Paul Taylor In this week's EuroBiotech Report, Catalan biotech Grifols secured a €100 million ($ 110 million) loan from the European Investment Bank's €315 billion ...

Roche backs €19M CNS round; CRUK puts £20M into cancer vax; In womb stem cell trial to start

Nick Paul Taylor In this week's EuroBiotech Report, Ysios Capital led a €19.4 million ($ 21.7 million) investment in Minoryx Therapeutics with the support of Roche Venture ...

U.K. cost gatekeeper says ‘OK’ to Merck’s Keytruda for advanced skin cancer

Emily Wasserman Merck's Keytruda got a green light from the U.K.'s cost effectiveness gatekeeper to treat patients with advanced skin cancer, chalking up another victory as ...

Geron jumps as its J&J-partnered cancer drug shows promise in Phase II

Damian Garde Long-troubled drug developer Geron is touting what it calls "unprecedented" early results for its lead cancer drug, sending the biotech's share price up as ...

Genzyme vets raise $37.5M for a new cancer biotech

Damian Garde The stealthy X4 Pharmaceuticals, run by some of former Genzyme execs, has raised $ 37.5 million to fund its work on new cancer treatments. FierceBiotech News

UPDATED: Verastem shares crater on Twitter chatter around cancer data

John Carroll Shares of Verastem cratered Wednesday morning as the Twitter crowd passed around an abstract on the company's defactinib (VS-6063), highlighting an extremely poor response ...

Syndax banks an $80M crossover round for PhIII cancer drug

John Carroll Two months after signing up AstraZeneca R&D leader Briggs Morrison as its new CEO, Waltham, MA-based Syndax has raised $ 80 million from a syndicate that includes ...

NICE plots takeover of England’s Cancer Drugs Fund

Emily Wasserman England's Cancer Drugs Fund has been dealing with budget overruns and backlash from drugmakers and patients unhappy with the fund's decision to ax certain meds ...

Novo Nordisk ties the R&D knot with Genmab, and they’re not focused on cancer

John Carroll Novo Nordisk is jumping on Genmab's antibody development platform in search of two new drug programs–and this time the Danish biotech company will not be focused ...

Roche dumps its cancer drug R&D pact with Wilex

John Carroll Roche is bowing out of a two-year-old collaboration with a subsidiary of a struggling Wilex. FierceBiotech News

Celgene buys into GlobeImmune’s cancer immunotherapy

Damian Garde GlobeImmune, reeling from a costly clinical failure, secured a commitment from long-time partner Celgene to collaborate on a new cancer immunotherapy. FierceBiotech News
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS